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Abstract
DIAGNOSTIC AGENTS—Nanoparticles functionalized with ligands that target tumors can be
cleared from the body through the kidneys if they have a hydrodynamic diameter of less than 5.5
nm.
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INTRODUCTORY PARAGRAPH
Inorganic/organic hybrid nanoparticles are potentially useful in biomedicine but to avoid non-
specific background fluorescence and long-term toxicity, they need to be cleared from the body
within a reasonable time scale.1 Previously, we showed that rigid spherical nanoparticles such
as quantum dots can be cleared by the kidneys if they had a hydrodynamic diameter less than
5.5 nm and a zwitterionic surface charge.2 Here we show that quantum dots functionalized
with high-affinity small molecule ligands that target tumors can also be cleared by the kidneys
if their hydrodynamic diameter is less than this value, which sets an upper limit of 5-10 ligands
per quantum dot for renal clearance. Animal models of prostate cancer and melanoma show
receptor-specific imaging and renal clearance within 4 h post-injection. This study suggests a
set of design rules for the clinical translation of targeted nanoparticles that can be eliminated
through the kidneys.
Although many classes of biocompatible, inorganic-based nanomaterials have been developed
for medical diagnostics and therapeutics,3-7 many presently available formulations require
potentially toxic elements.8 Efforts have been made to reduce toxicity by modulating the
composition, particle shape, physical size, and surface coating of the nanoparticles.9 One
common strategy is to engineer nanoparticles using biocompatible and biodegradable
polymeric coatings.10-13 However, polymer coatings generally increase particle size over the
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desired range, which can result in nonspecific background, long circulation times, and
accumulation over time into the reticuloendothelial system (RES; i.e., liver, spleen, lymph
nodes, and bone marrow).12,14 In addition, polymer coatings may activate inflammatory or
immunological responses,15 and the degradation of polymer coatings leads to exposure of
inorganic surfaces, which can do the same.16,17
Clinical translation of nanotechnology will require nanoparticles with the lowest possible
likelihood of toxicity. One important strategy to minimize toxicity is to remove all unbound
material completely from the body, that is, excrete it via the liver (into bile) or via the kidneys
(into urine). Whereas hepatic clearance is unpredictable and variable,18,19 renal excretion tends
to follow predictable rules.2 Yet, to date, there have not been any nanoparticles described that
can target a disease state, as well as be cleared efficiently from the body in a reasonable amount
of time.
In 2004, Gao et al.4 reported a landmark paper on in vivo cancer targeting with semiconductor
quantum dots, and since that time numerous additional papers on this topic have been
published.20-23 However, most of these papers fail to consider the autofluorescence of living
tissue, the passive targeting caused by leaky tumor vasculature, the use of a receptor-negative
tumor as a control, and the high background accumulation of nanoparticles in the RES. Indeed,
most tumor targeting of nanoparticles in animals described to date is likely the result of
enhanced permeability and retention,24 and not specific targeting.
To render nanoparticles viable for clinical translation, it is necessary to understand the key
design considerations that govern their behavior in vivo. Starting with ultrasmall, zwitterionic
quantum dots (QDs) previously described by our group2 as a model system, we hypothesized
that it should be possible to define the ligand properties, ligand conjugation ratio,
hydrodynamic diameter (HD), and surface characteristics that permit tumor-specific targeting
in a living system, and to develop targeted nanoparticles that are eliminated completely from
the body if not bound to the desired tumor.
To demonstrate the generality of the technology, we developed two different types of QDs,
one targeting prostate-specific membrane antigen (PSMA)-positive prostate cancer cells via
the small molecule ligand GPI,25 and one targeting integrin αvβ3-positive melanoma cells via
the small molecule cRGD.26 We prepared ultrasmall CdSe(ZnCdS) core(shell) nanocrystals
that were rendered aqueous-soluble with a zwitterionic cysteine coating (Fig. 1a),2,27 while
retaining a reasonably high quantum yield (28%). To minimize the impact of tissue
autofluorescence and to improve in vivo detectability, we conjugated ≈1.4 molecules of the
organic NIR fluorophore IRDye™800-CW to each visibly fluorescent QD (QD-CW) prior to
ligand conjugation. Finally, high-affinity small molecule targeting ligands were conjugated
covalently to the carboxylic groups of the QD surface using standard carbodiimide chemistry
to form QD-CW-GPI or QD-CW-cRGD (see Supplementary Methods). Although the cysteine-
coated core(shell) nanocrystals were small enough to be excreted via the kidneys, the number
of conjugated ligands needed to be limited such that the overall HD was ≈5.5 nm, which is
approximately the threshold for rapid renal excretion at 4 h post-injection.2 Using HD as
measured by gel-filtration chromatography, we determined that only 5 to 10 GPI or cRGD
small molecules could be conjugated to the QD-CW surface while still maintaining the small
HD needed for renal clearance (Fig. 1b). Importantly, though, QD-CW-GPI and QD-CW-
cRGD ligand prepared in this way did not show any binding to serum proteins, which would
lead to a further increase in HD (see Supplementary Methods).2
The specificity of QD-CW-GPI and QD-CW-cRGD binding to the surface of living cancer
cells was confirmed using human prostate cancer and melanoma cell lines. As shown in Fig.
2, QD-CW-GPI bound to PSMA-positive LNCaP human prostate cancer cells, but not to
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PSMA-negative PC-3 human prostate cancer cells. Similarly, QD-CW-cRGD showed
significant binding to αvβ3-positive M21 human melanoma cells, but not to αvβ3-negative M21-
L human melanoma cells.
To quantify QD biodistribution, blood levels, and clearance from the body, QDs were labeled
with 99mTc (Supplementary Methods and Fig. 3) and injected intravenously. The measured β-
phase blood half-lives (t1/2β) of 99mTc-QD-GPI and 99mTc-QD-cRGD were extremely similar,
being 126 min and 113 min, respectively. At 4 h post-injection, organs and tumors were
resected and activities were measured. The most intense uptakes for 99mTc-QD-GPI were
measured in the liver (9.6 ± 3.8 %ID), kidneys (5.1 ± 3.0 %ID), and intestine (1.9 ± 1.8 %ID)
(Fig. 3a), consistent with active excretion. Similarly, the remaining activity of 99mTc-QD-
cRGD was found in the liver (10.2 ± 5.7 %ID), kidneys (6.5 ± 2.5 %ID), and intestine (4.4 ±
3.2 %ID) (Fig. 3b). Importantly, over 65% of the ligand-targeted QDs were completely
eliminated by the body within 4 h post-injection, appearing primarily in the urine (Fig. 3c). At
24 h post-injection, total carcass retention was ≈9% for both targeted QDs (data not shown).
In vivo tumor targeting, biodistribution, and clearance of targeted QDs were demonstrated
using NIR fluorescence imaging. As shown in Fig. 4a, a large amount of QD-CW-GPI
accumulated in the LNCaP tumor site (PSMA-positive) over 4 h. The positive- to negative-
tumor ratio was 2.8 and the tumor-to-background ratio was 5.0. Cross-sectional imaging
revealed that QD uptake into solid tumors displayed expected variability, with some tumors
showing homogeneous uptake and others showing less homogenous uptake (see
Supplementary Methods). Most of the remaining QDs were excreted through renal filtration
and were found primarily in the bladder (Fig. 4a, Supine). Fluorescence imaging revealed that
apart from the kidneys and bladder, most tissues and organs had extremely low levels of
fluorescence (Fig. 4b). We further validated the tumor targeting and background-clearing
properties of our QDs using the cRGD/integrin system. Tumor accumulation was high, with a
positive- to negative-tumor ratio of 5.1 and a tumor-to-background ratio of 6.9. Once again,
excretion was primarily renal, with most of the injected dose appearing in the urine (Fig. 4c,d).
Confirming these results, urine collected 4 h post-injection of QD-CW-GPI and QD-CW-
cRGD was highly fluorescent, and had a gel-filtration chromatography pattern very similar to
QDs in PBS (Fig. 5).
There are three major challenges with using nanoparticles as in vivo diagnostics and
therapeutics: 1) high background retention in the RES, 2) lack of complete elimination from
the body, and 3) arriving at an HD small enough for rapid equilibration between the
intravascular and extravascular spaces. Solving all of these problems, while maintaining high
specificity for desired targets, is extremely difficult. In previous work, we demonstrated that
an HD ≤ 5.5 nm was required for efficient renal clearance of spherical nanoparticles.2 In the
present study, we show that it is indeed possible to target renally-cleared QDs to tumors, but
the HD increase due to the targeting ligand(s) is severely limiting. Only 5 to 10 small molecule
ligands could be conjugated to the surface of QDs before the increased HD precluded rapid
renal clearance. Nevertheless, using this strategy, the majority of the injected, unbound dose
was excreted by 4 h, while receptor-specific targeting was preserved. Interestingly, the ability
to control the number of targeting ligands on the QD surface while maintaining renal clearance
preserves the option of using “multiplexed” targeting. That is, it should be possible to conjugate
two (or more) different targeting ligands to the QD surface to more effectively target tumors
that express multiple receptor types.4,28
With many inorganic/organic hybrid nanoparticle systems, it remains a challenge to generate
a final HD of ≈5.5 nm.29 The nanocrystals used in this study might actually represent a worst-
case scenario, since the organic NIR fluorophore molecule occupies surface area that could
have otherwise been used for a small molecule targeting ligand. Our data may also be applicable
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to larger nanoparticles, provided that they degrade to renally-filterable metabolites. If
degradation occurs before uptake by the RES, renal elimination should be efficient, even if the
degradation products contain targeting ligands.17 The only caveat is surface charge, and thus,
the charge to HD ratio. Highly anionic or cationic QDs and their fragments have a tendency
to bind serum proteins and increase their HD.2 This is one of the key reasons why we began
with a zwitterionic surface coating and were careful to minimize the number of anionic
targeting ligands, such as GPI and cRGD, conjugated to this coating.
Finally, the desired HD of ≈5.5 nm is for “rapid” renal clearance, i.e., the majority of the dose
being eliminated by 4 h. Four hours is chosen as the key imaging time because it is “clinically
realistic” for human surgery. For example, the dose could be given as soon as the patient arrives
in the pre-op area, thus providing an imaging window that would last for several hours during
image-guided surgery.30 For nanoparticles with an HD slightly larger than the threshold, it
might still be possible to eliminate them in urine, but longer clearance times would be
necessary.
We report the rules for designing tumor-targeted nanoparticles for in vivo imaging that can be
renally cleared using QDs as a model particle. We hope this study will lay the foundation for
designing targeted nanoparticles with the optimal composition, particle size, and surface
coating to control biodistribution, elimination from the body, and receptor-based targeting.
Finally, elimination in urine helps negate concerns over toxicity, thus making clinical
translation more viable.
METHODS
Synthesis of QD-CW-GPI and QD-CW-cRGD
Aqueous-soluble, cysteine-coated CdSe(ZnCdS) core(shell) nanocrystals with a HD of 3.4 nm
were synthesized according to previous studies.2,27 Near-infrared fluorophore IRDye800-CW
(LI-COR, Lincoln, NE) was conjugated covalently to the QD surface (QD-CW) in PBS, pH
7.8 to a labeling ratio of 1.4. QD-CW was resuspended in 0.1 M 2-(N-morpholino)
ethanesulfonic acid (MES) at pH 6, and treated with carbodiimide 1-ethyl-3-(3-
dimethyllaminopropyl)carbodiimide (EDC; Pierce) and sulfo-NHS (Pierce). The suspension
was incubated for 15 min, and excess reagents removed by ultrafiltration. GPI (2-[((3-amino-3-
carboxypropyl)(hydroxy)phosphinyl)-methyl]pentane-1,5-dioic acid)25 or cRGD (monomeric
cyclic Arg-Gly-Asp peptide)26 was dissolved in PBS, pH 8.0, and mixed with the MES
solution. After a 3 h reaction, the mixtures were subjected to ultrafiltration with Tris (pH 8.0)
to remove any unconjugated dye and to quench unreacted NHS ester. The labeling ratio was
determined by UV-Vis absorption measurements (labeling ratio = 5 - 10). See Supplementary
Methods for detailed experimental methods.
Gel-filtration chromatography
Details of the custom chromatography system, which permits on-line, full-spectrum analysis
of QD absorbance and fluorescence, have been published previously.30 Calibration of HD was
performed by injecting 100 μL of protein standards containing γ-globulin (M1, 158 kDa, 11.9
nm HD), ovalbumin (M2, 44 kDa, 6.13 nm HD), myoglobin (M3, 17 kDa, 3.83 nm HD), and
vitamin B12 (M4, 1.35 kDa, 1.48 nm HD). All HD measurements were performed with three
independent experiments. For measurement of the effects of serum protein adsorption, 2.5
μM QDs were incubated in PBS or 100% mouse serum for 4 h at 37°C prior to loading 100
μL onto the column.
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In vitro cell binding studies
The human prostate cancer cell lines LNCaP (ATCC, Manassas, VA) and PC-3 (ATCC,
Manassas, VA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Mediatech,
Hermdon, VA), supplemented with 10% FBS and 5% penicillin/streptomycin under a 5%
carbon dioxide atmosphere. Human M21 and M21-L melanoma cells were grown in RPMI
1640 (Mediatech, Hermdon, VA). Cells were seeded onto sterilized 18-mm-diameter glass
coverslips in 12-well plates (3 × 105 cells per well), and incubated overnight at 37°C. Cells
were then washed with PBS and incubated in pre-cooled, serum-containing medium at 4°C in
the presence of 0.5 μM QD-CW-GPI or 1 μM QD-CW-cRGD for 30 min. They were then
washed with PBS and fixed with 2% paraformaldehyde at room temperature for 10 min. The
slides were observed on a previously described four-channel NIR fluorescence microscope.25
Intraoperative fluorescence imaging of tumor-bearing mice
An intraoperative fluorescence imaging system optimized for animal surgery has been
described in detail previously.30 For fluorescence excitation, LEDs (Marubeni Epitex, New
York, NY) fitted with 760 ± 20 nm (NIR) or 470 ± 20 nm (blue) excitation filters in custom
holders were used. The emission filter was a 795 nm long pass. Exposure time (200 ms) and
normalizations were the same for all fluorescence images. Color video was collected on a
separate optical channel using computer-controlled camera acquisition via custom LabVIEW
software (National Instruments, Austin, TX).
Biodistribution and clearance
100 μL of 2.5 μM 99mTc-labeled QDs (see Supplementary Methods) were administered
intravenously into 25 g CD-1 mice (~100 μCi). Mice were housed in special cages to allow for
the collection of urine and feces. Measurement of blood clearance was performed by
intermittent sampling of the tail vein. Mice were sacrificed 4 h post-injection. To measure total
urinary excretion, the ureters and urethra were ligated with silk sutures, and the bladder
removed en masse and combined with excreted urine, prior to measurement of radioactivity in
a dose calibrator. The remaining carcass was also measured in a dose calibrator, then the skin,
adipose, muscle, bone, heart, lungs, spleen, liver, kidneys, stomach, intestine, brain, and feces
were resected, washed twice in PBS, pH 7.4, weighed, and their radioactivity measured on a
Wallac Wizard (model 1470, Perkin Elmer, Wellesley, MA) 10-detector gamma counter. Curve
fitting was performed using Prism version 4.0a software (GraphPad, San Diego, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Design and characterization of nanoparticles. a, Chemical conjugation of targeting ligands (R)
and NIR fluorophores with cysteine-coated CdSe(ZnCdS) core(shell) QDs. b, Absorption
(Abs) and fluorescence (FL) emission (λExc = 532 nm) spectra (top panels) of QD545 (left)
and QD-CW (right). Gel-filtration chromatography (mobile phase = PBS, pH 7.4) analysis
(bottom panels) of the different nanoparticles in PBS (left) and after 4 h incubation in 100%
mouse serum (right). λExc = 532 nm. Molecular weight markers M1 (γ-globulin; 158 kDa, 11.9
nm HD), M2 (ovalbumin; 44 kDa, 6.13 nm HD), M3 (myoglobin; 17 kDa, 3.83 nm HD), and
M4 (vitamin B12, 1.35 kDa, 1.48 nm) are shown by arrows.
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Live cell binding of targeted QDs in vitro: NIR fluorescence imaging of QD-CW-GPI after
incubation with PSMA-positive LNCaP and PSMA-negative PC-3 prostate cancer cells (left),
and of QD-CW-cRGD after incubation with αvβ3-positive M21 and αvβ3-negative M21-L
melanoma cells (right). For each are shown phase contrast (left) and NIR fluorescence (right)
images. Fluorescence images have identical exposure times and normalizations. Scale bar =
10 μm.
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Total body clearance of targeted nanoparticles 4 h post-intravenous injection into CD-1 mice.
Each data point is the mean ± S.D. from n = 4 animals. Blood concentration (%ID/g) and organ
distributions (%ID) for 99mTc-QD-GPI (a) and 99mTc-QD-cRGD (b). c, Elimination in
excrement (white) and retained dose in carcass (black) of 99mTc-QD545, 99mTc-QD-GPI,
and 99mTc-QD-cRGD.
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In vivo fluorescence imaging of human prostate cancer and melanoma xenograft tumors. a, 10
pmol/g (0.2 μg/g) of QD-CW-GPI was injected intravenously and observed for 4 h. The PSMA-
positive LNCaP tumor (T+) and PSMA-negative PC-3 tumor (T-) are indicated. Shown are
representative (n = 5 animals) images of color video (left) and NIR fluorescence (right) for
animals in prone (left) or supine (right) position. b, In situ (top row) and resected (bottom row)
organs from (a) were imaged 4 h post-injection with color video (left) and NIR fluorescence
(right). c, 10 pmol/g (0.2 μg/g) of QD-CW-cRGD was injected intravenously and observed for
4 h. The αvβ3-positive M21 tumor (T+) and αvβ3-negative M21-L tumor (T-) are indicated.
Shown are representative (n = 5 animals) images of color video (left) and NIR fluorescence
(right) for animals in prone (left) or supine (right) position. d, In situ (top row) and resected
(bottom row) organs from (c) were imaged 4 h post-injection with color video (left) and NIR
fluorescence (right). Ki, kidneys; Du, duodenum; Sp, spleen; In, intestine; Lu, lungs; Li, liver;
Pa, pancreas; Ab, abdominal wall; and Bl, bladder.
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HD measurements of renally excreted QDs: QD-CW-GPI (solid curve) and QD-CW-cRGD
(dotted curve) in PBS (left) and in urine collected 4 h post-injection (right). λExc = 770 nm.
Molecular weight markers (arrows) are as described in Fig. 1b.
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